Key Points
- To review the molecular signaling networks controlling myofibroblast activation and evaluate targeted therapeutic strategies for treating cardiac fibrosis.
- Synthesized recent literature on cellular mechanisms driving fibroblast differentiation and tissue repair.
- Assessed the interconnected roles of TGF-beta, endothelin-1, angiotensin II, CCN2, and PDGF in fibrotic remodeling.
- Examined pharmacological agents designed to block these pathways to mitigate fibrotic progression in the heart.
- Myofibroblasts expressing alpha-smooth muscle actin drive pathological extracellular matrix accumulation and sustain fibrotic damage.
- A cooperative network of TGF-beta, endothelin-1, Ang II, CCN2, and PDGF signaling maintains myofibroblast persistence in injured tissue.
- Inhibiting these growth factor and cytokine pathways qualitatively reduces fibroblast activation and represents a viable strategy for cardiac fibrosis therapy.
Structured PICO
IInterventionDrugs targeting TGFbeta, endothelin-1, Ang II, CCN2, and PDGF
This review highlights the potential of targeting proteins like TGFbeta, endothelin-1, Ang II, CCN2, and PDGF to inhibit myofibroblast persistence and treat cardiac fibrosis.